Industry News
Pharmaceutical Industry News
Havas will lead Indivior’s…
Havas will lead Indivior’s integrated strategy, creative, media and digital efforts across healthcare professional and direct-to-consumer audiences.
With a new corporate sponsorship…
With a new corporate sponsorship in hand, Ardelyx is aiming for a hole-in-one in the awareness-raising game.
The new plants are the latest in a…
The new plants are the latest in a string of recent investments AbbVie has made in U.S. manufacturing, filling out the company's plan to infuse $100 billion into its American operations over the next decade.
Roche’s Enspryng is making solid…
Roche’s Enspryng is making solid progress as a treatment for neuromyelitis optica spectrum disorder. But the company’s efforts to expand its use to a new indication is coming up short.
With the Supreme Court’s rebuke…
With the Supreme Court’s rebuke of President Donald Trump’s emergency tariffs Friday, the U.S. administration’s international trade agenda is facing a new threat. At least one major partner has pumped the brakes on a deal
Bayer has filed a false…
Bayer has filed a false advertising lawsuit taking issue with claims made by Johnson & Johnson to pit their prostate cancer drugs against one another.
With a productive working…
With a productive working relationship between the two companies already well established, Bora Pharmaceuticals is renewing a $250 million global manufacturing agreement with British drugmaker GSK.
Vanda Pharmaceuticals is riding a…
Vanda Pharmaceuticals is riding a regulatory roller coaster over the last few months with two FDA approvals and one rejection. On Friday, the U.S. regulator signed off on Vanda's Bysanti, an atypical antipsychotic treatment for
The patent cliff for Keytruda is…
The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming medicines
The trend of rising FDA voucher…
The trend of rising FDA voucher prices is continuing as 2026 plays out, with another transaction now valued at $200 million or more.
What to Know Before Buying Weight Loss Drugs Online
Many patients are getting GLP-1s from websites and medical spas. But there’s much less oversight.
About a month after securing a…
About a month after securing a label expansion from the FDA for multidose pen versions of Zepbound, Eli Lilly is making the KwikPens available to self-paying users of its direct-to-consumer drug sales platform.
Catalent is cutting more roles at…
Catalent is cutting more roles at its gene therapy manufacturing facility in Harmans, Maryland. This round of layoffs will affect 93 employees at the Harmans facility and three more in nearby Baltimore.
Community oncology is redefining…
Community oncology is redefining cancer care—advancing innovation, expanding trial access and keeping high-quality treatment close to home.
The new proposed board members…
The new proposed board members come after an extraordinary general meeting last fall saw a significant change in leadership.
Gilead penned a potential $1.5…
Gilead penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. A cell therapy company could end a one-year-plus biotech IPO drought in Tokyo. Novo Nordisk faces increased GLP-1 competition in China. And
After the pharmaceutical industry…
After the pharmaceutical industry spent much of the past year safeguarding its businesses against the threat of U.S. import tariffs, a new Supreme Court ruling now waylays the Trump administration's trade agenda—at least in part.
AstraZeneca has secured a key…
AstraZeneca has secured a key regulatory win in its effort to reclaim the lead in the BTK inhibitor market, with the FDA approving its Calquence plus Venclexta as the first all-oral, fixed-duration regimen for first-line
After manufacturing the antibiotic…
After manufacturing the antibiotic Rocephin for four decades—and developing it into one of the company’s first blockbuster medicines—Roche is looking to divest the treatment and its production facility near its headquarters in Switzerland.
Novartis will transfer its 70.68%…
Novartis will transfer its 70.68% stake in Novartis India Limited—a Bombay Stock Exchange-listed company that primarily handles older and off-patent drugs in areas like immunology, neuroscience and pain—to a group of private equity firms.